Short‐Course of Oral Miltefosine for Treatment of Visceral Leishmaniasis | Zendy

Shyam Sundar | Zendy; Anand Makharia | Zendy; Deepak K. More | Zendy; Gaurav Agrawal | Zendy; Andreas Voß | Zendy; Christina Fischer | Zendy; Peter Bachmann | Zendy; Henry W. Murray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Short‐Course of Oral Miltefosine for Treatment of Visceral Leishmaniasis

Author(s) -

Shyam Sundar,

Anand Makharia,

Deepak K. More,

Gaurav Agrawal,

Andreas Voß,

Christina Fischer,

Peter Bachmann,

Henry W. Murray

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/318122

Subject(s) - miltefosine , medicine , visceral leishmaniasis , regimen , group b , dosing , leishmaniasis , group a , adverse effect , gastroenterology , surgery , dermatology , immunology

A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research